Latest Breaking News On - Arch pathol lab - Page 1 : comparemela.com

Ibex Launches Galen™ Breast HER2, Supporting Improved Biomarker Scoring in Breast Cancer Patients

IMFINZI-based treatment before and after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable non-small cell lung cancer in the AEGEAN Phase III trial

Results presented at AACR 2023 found that four times as many patients treated with Imfinzi plus chemotherapy before surgery achieved pathologic complete response versus those treated with neoadjuvant. | April 16, 2023

PathGroup Chooses Proscia To Deliver Next Generation Of Cancer Diagnosis For Millions of Patients

NASHVILLE and PHILADELPHIA (PRWEB) March 01, 2023 Proscia®, a leading provider of digital and computational pathology solutions, today announced

Daiichi Sankyo: ENHERTU Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast Cancer

Approval based on DESTINY-Breast04 results where Daiichi Sankyo and AstraZeneca's ENHERTU reduced the risk of disease progression or death by 50% and increased median overall survival by more than

ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast Cancer